Skip to content
akaturk Academic measurement

Article detail · 2015 · article

Current Helicobacter pylori treatment in 2014

Journal World Journal of Methodology
ISSN2222-0682
YÖKSİS OpenAlex Open access · diamond
Year2015
Citations18OpenAlex
Citations21Semantic Scholar
Percentile%86.3
FWCI2.01.00 = world average

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueWorld Journal of Methodology
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

Helicobacter pylori is one of the most commonly seen bacterium worldwide. It's in the etiology of multiple gastrointestinal diseases, ranging from gastritis to gastric carcinoma. The antimicrobial therapies, which are frequently prescribed empirically, are losing their effectivity as a result of the increasing antimicrobial resistance. As the standard triple therapy is now left especially in areas with high-clarithromycin resistance due to decreased eradication rates, quadruple therapies are recommended in most regions of the world. Alternatively, concomitant, sequential and hybrid therapies are used. There is still a debate going on about the use of levofloxacin-based therapy in order to prevent the increase in quinolone resistance. If no regimen can achieve the desired eradication rate, culture-guided individualized therapies are highly recommended. Probiotics, statins and n-acetylcysteine are helpful as adjuvant therapies in order to increase the effectiveness of the eradication therapy. Herein, we focused on different eradication regimens in order to highlight the current Helicobacter pylori treatment.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

18citationsOpenAlex · cited_by_count (cache / database)

3 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2020 The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated GastritisCitations 5 · OpenAlex
  2. 2021 Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must ChangeCitations 4 · OpenAlex
  3. 2021 Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must ChangeCitations 4 · OpenAlex

Authors

2
  1. FATİH ERMİŞ 1
  2. ELİF ŞENOCAK TAŞÇI ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ 2